欧洲国家对WHO重点耐药菌的法定监测与暴发报告现状
该研究旨在评估欧盟28国及欧洲自由贸易联盟4国对WHO 2017年12种重点耐药菌的法定监测与暴发报告系统。
要点
- 仅66%欧洲国家法定监测至少一种WHO重点耐药菌,暴发报告仅19%。
- 监测最常覆盖碳青霉烯耐药肠杆菌目、MRSA和万古霉素耐药肠球菌。
- 无欧洲国家要求报告沙门菌、弯曲杆菌、幽门螺杆菌和淋病奈瑟菌耐药。
核心结论
- 尽管耐抗生素细菌负担增加,极少数欧洲国家实施WHO重点病原体的法定监测和暴发报告。
- 需国际努力评估法定报告的有效性及其在减少耐药菌传播中的作用。
研究设计与样本
- 横断面映射研究,覆盖欧盟28国及欧洲自由贸易联盟4国,通过审查国家文件(无语言限制)和专家咨询收集信息。
主要发现
- 监测覆盖碳青霉烯耐药肠杆菌目(12国;38%)、MRSA(12国;38%)、万古霉素耐药肠球菌(8国;25%)。
- 临床结局和风险因素报告分别仅见于22%和25%的国家。
- 仅6国(19%)实施至少一种WHO重点病原体的法定暴发报告。
关键数值与推荐
- 无欧洲国家要求报告沙门菌、弯曲杆菌、幽门螺杆菌和淋病奈瑟菌的耐药性。
- 数据收集、报告和传播方式高度异质。
临床怎么用
- 感染科医生应了解本国对WHO重点耐药菌的法定监测范围有限,暴发报告系统覆盖不足。
- 临床中需关注未纳入法定监测的耐药菌(如沙门菌、弯曲杆菌、幽门螺杆菌、淋病奈瑟菌)的耐药情况。
局限性
- 仅对开放获取系统进行定性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In 2017 the WHO published a global priority list of 12 antibiotic-resistant bacteria (ARB) in urgent need of new antibiotics. We aimed to identify and assess publicly accessible mandatory surveillance systems and outbreaks reporting for these pathogens in the 28 European Union and four European Free Trade Association member states. METHODS: Compulsory reporting was mapped by reviewing national documents without applying language restrictions and through expert consultation. Information on surveillance targets, indicators, metrics and dissemination modalities was extracted and a qualitative assessment was performed for open access systems only. RESULTS: Twenty-one countries (66%) had a mandate to survey at least one among the 12 WHO priority pathogens; 15 provided access to surveillance frameworks. These systems covered most frequently carbapenem-resistant Enterobacteriales (12; 38%), methicillin-resistant Staphylococcus aureus (12; 38%), and vancomycin-resistant enterococci (8; 25%). None of the European countries required reporting of resistance in Salmonella, Campylobacter, Helicobacter pylori and Neisseria gonorrhoeae. High heterogeneity was observed in data collection, reporting and dissemination among countries with clinical outcomes and risk factors being reported in less than half (22% and 25%). Only six countries (19%) implemented mandatory surveillance of outbreaks due to at least one WHO priority pathogen. CONCLUSIONS: Our review shows that despite the increasing burden of ARB on the European population, very few countries implemented mandatory surveillance and outbreak reporting of the WHO priority pathogens. International efforts are needed to define the effectiveness of implementing mandatory reporting of these pathogens and to assess their role in reducing the spread of ARB in health-care and community settings.
引用
- Babu Rajendran N, Mutters NT, Marasca G, et al. Mandatory surveillance and outbreaks reporting of the WHO priority pathogens for research & discovery of new antibiotics in European countries. Clin Microbiol Infect. 2019. PMID: 31812771. doi:10.1016/j.cmi.2019.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。